Procollagen Type III, human, bovineCatalog number: CO23311-0.1
Collagen type III is synthesized as a homo-trimeric pro-collagen comprising three identical pro-alpha(III)-chains. It has been reported that procollagen type III is processed extracellularly at the ECM and can be found by immunostaining intracellular as well as extracellular. Collagens consist of a family of highly specialized glycoproteins of which at least 16 genetically distinct types are known to date. The basal unit of a collagen molecule consists of a triple-helical structure formed by 3 alpha-chains. Predominant amino acids are glycine, proline and hydroxproline. Regularly also lysines and hydroxylysines occur, which are responsible for cross-linkage and glycosylation of the protein chains. Different composition of alpha-chains and different glycosylation contribute to the high variability of collagens in different tissues and organs. Human and bovine procollagen type III (PIIIP) 100%; human and bovine procollagen type and collagen type I <0.1% in RIA at 1:200 dilution..
Immunogen: Procollagen type III deprived of the C-terminal PIIICP peptide
affinity purified antibody lyophilized from phosphate buffered solution; no BSA and preservative added!
Purification Method: affinity purified antibody lyophilized from phosphate buffered solution; no BSA and preservative added!
Secondary Reagents: Anti-rabbit IgG-conjugates, e.g. anti-rabbit IgG:FITC (Art. No. FI-1000) or anti-rabbit IgG:DyLight488 (Art. No. DI-1488).
Concentration: app. 1 mg/ml
Species Reactivity: Human, cattle (pig)
IHC(P), IFA, ELISA, RIA, IB/WB
Incubation Time: IHC(P) 60 min at RT or 2-8°C over night
Working Concentration: (purified, lyophilized) IFA ? 1:40, IHC(P) ? 1:500, ELISA 1:100 - 1:200 (OD ? 500), RIA >1:200
Pre-Treatment: After de-waxing the tissue slices they are treated with 0.2% hyaluronidase (app. 300 U/mg e.g. Art. No. HYA02-50) in TBS 15 min at 37°C. Thereafter non-specific binding is blocked by blocking serum or 3% BSA in TBS. For peroxidase systems blocking with 1% peroxide solution in TBS for 30 min at RT is recommended.
Positive Control: Human or bovine skin and liver
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Desmoulière A., Darby I., Monte Alto Costa A., Raccurt M., Tuchweber B., Sommer P., Gabbiani G. (1997) Extracellular Matrix Deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab. Invest. 76, 765-778. 2. Gindre D., Peyrol S., Raccurt M., Sommer P., Loire. R., Grimaud J.A., Cordier J.F. (1995) Fibrosing vasculitis in Wegener's granulomatosis: ultrastructural and immunohistochemical analysis of the vascular lesions. Virchows Arch. 427, 385-393. 3. Trinchet J.C., Hartmann D.J., Pateron D., Munz-Gotheil C., Callard P., Ville G., Beaugrand M. (1992) Serum type I collagen and N-terminal peptide of type III procollagen in patients with alcoholic liver disease: relationship to liver histology. Alcohol. Clin. Exp. Res. 16, 342-346.
Database Name: UniProt
Accession Number: P02461 (CO3A1_HUMAN)
Species Accession: Human